The development of antibiotic resistance during treatment is a threat to patients and their 29 environment. Insight in the mechanisms of resistance development is important for 30 appropriate therapy and infection control. Here, we describe how through the application of 31 mass spectrometry-based proteomics, a novel beta-lactamase Axc was identified as an 32 indicator of acquired carbapenem resistance in a clinical isolate of Achromobacter 33 xylosoxidans. 34 Comparative proteomic analysis of consecutively collected susceptible and a resistant 35 isolates from the same patient revealed that high Axc protein levels were only observed in 36 the resistant isolate. Heterologous expression of Axc in Escherichia coli significantly 37 increased the resistance towards carbapenems. Importantly, direct Axc mediated hydrolysis 38 of imipenem was demonstrated using pH shift assays and 1 H-NMR, confirming Axc as a 39 legitimate carbapenemase. Whole genome sequencing revealed that the susceptible and 40 resistant isolates were remarkably similar. 41 Together these findings provide a molecular context for the fast development of 42 meropenem resistance in A. xylosoxidans during treatment and demonstrate the use of 43 mass spectrometric techniques in identifying novel resistance determinants. 44 45 46 47
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The development of antibiotic resistance during treatment is a threat to patients and their 29 environment. Insight in the mechanisms of resistance development is important for 30 appropriate therapy and infection control. Here, we describe how through the application of 31 mass spectrometry-based proteomics, a novel beta-lactamase Axc was identified as an 32 indicator of acquired carbapenem resistance in a clinical isolate of Achromobacter 33 xylosoxidans. 34 Comparative proteomic analysis of consecutively collected susceptible and a resistant 35 isolates from the same patient revealed that high Axc protein levels were only observed in 36 the resistant isolate. Heterologous expression of Axc in Escherichia coli significantly 37 increased the resistance towards carbapenems. Importantly, direct Axc mediated hydrolysis 38 of imipenem was demonstrated using pH shift assays and 1 H-NMR, confirming Axc as a 39 legitimate carbapenemase. Whole genome sequencing revealed that the susceptible and 40 resistant isolates were remarkably similar. 41 Together these findings provide a molecular context for the fast development of Development and spread of antibiotic resistance by pathogenic microorganisms is an 50 increasing healthcare problem. Moreover, certain resistance determinants spread readily 1,2 , 51 while the introduction of novel antibiotics is lagging behind. Several clinically important 52 classes of antimicrobials such as the beta-lactams, target the bacterial cell wall 3 . Resistance 53 to beta-lactams can be mediated by beta-lactamases that are capable of hydrolysing the 54 beta-lactam ring. Following the initial introduction of penicillin, second and third generation 55 beta-lactams have been developed which, in turn, triggered the selection of beta-56 lactamases with broader specificities. Carbapenem treatment is often used as a last resort, 57 since extended-spectrum beta-lactamases (cephalosporinases) are becoming more 58 prevalent in Gram-negative bacteria. The emergence and spread of carbapenemases such as 59 class A KPC 4 , a number of metallo beta-lactamases 5,6 (class B: IMP, VIM, NDM) and class D 60 oxacillinases such as OXA-48 7 , in combination with other resistance mechanisms 8 , can 61 jeopardize carbapenem efficacy, leaving little or no treatment options for patients. 62 Achromobacter xylosoxidans is a rod shaped aerobic non-fermentative Gram-63 negative bacterium. It is widespread in the environment and generally considered as an 64 opportunistic pathogen. Chronic infections with A. xylosoxidans are problematic in cystic 65 fibrosis patients 9,10 but reported prevalence numbers vary greatly (3-30%) 11, 12 . Moreover, 66 bacteremia as a result of A. xylosoxidans can occur in immunocompromised patients 13 . A. 67 xylosoxidans is notorious for its intrinsic high level of resistance, especially towards 68 penicillins and cephalosporins [14] [15] [16] . In general, carbapenem resistance in A. xylosoxidans is 69 not widespread and as a result meropenem treatment is routinely applied, even in the case 70 of recurring infections 17, 18 . Though carbapenem resistance is observed, specifically for 71 meropenem 19 , there are few reports on the mechanism of carbapenemase resistance in A. 72 xylosoxidans. Notable exceptions are the plasmid-encoded carbapenemase IMP 20,21 and the   73   chromosomally encoded class D beta-lactamase Table 1 ). Subsequently, pure cultures from the first 105 and second clinical isolate were prepared (AchroS and AchroR, respectively). In line with the 106 antibiogram analysis described above, Etests showed that both isolates were resistant to 107 imipenem (MIC > 32 mg/L for both) but differed in their susceptibility towards meropenem 108 (MIC of 0.0094 mg/L (first isolate, AchroS) and 2 mg/L (second isolate, AchroR), 109 respectively). An in-house multiplex PCR assay (based on a published PCR 34 ) failed to detect 110 common carbapenemases (KPC, IMP, VIM, NDM and OXA-48, data not shown), suggesting 111 that the change in resistance is not mediated by these enzymes. This finding prompted us to 112 perform a comparative proteomic analysis of the two isolates to attempt to identify the 113 meropenem resistance mechanism. instance. In those strains that contain axc, the gene is located next to a putative LysR-type Our results show a high degree of similarity between the meropenem resistant and 162 susceptible strain, raising the possibility that these two strains represent a clonal complex. 163 To further explore the relatedness of both isolates, whole genome sequencing (WGS) 164 analysis was performed. This showed that both patient isolates are highly similar, with only 165 one single-nucleotide polymorphism (SNP) within the gene encoding AxyZ 36 . This SNP was 166 confirmed by PCR and subsequent Sanger sequencing, ruling out the possibility that this was 167 an artefact of the assembly procedure. Moreover, axc and its putative regulator axcR were 168 found to be located in the same genomic region as in NH44784_1996 strain (Figure 2A ). 169 Overall, the genome sequences suggest that both isolates are clonal, and that the 170 meropenem resistance evolved within the same strain during the course of treatment. 171 To demonstrate how Axc is related to other class A beta-lactamases, we compared 172 the Axc amino acid sequence with the sequence of another 176 representatives of this 173 family using an alignment consensus based on a report by Walther-Rasmussen and Hoiby 37 . 174 The resulting unrooted cladogram shows that Axc is most closely related to a class A beta-175 lactamase of Rhodoferax saidenbachensis (WP_029709665, Figure 2B ). Only a limited 176 number of class A beta-lactamases have activity towards carbapenems, but none of these 177 cluster with the Axc sequence ( Figure 2B ). Our data therefore suggest a novel function for 178 the PenP family of beta-lactamases (COG2367) to which Axc belongs. To establish whether Axc indeed has activity towards carbapenems, Axc was expressed in a 182 heterologous host and hydrolysis of carbapenems was measured indirectly and directly. 183 The E. coli C43 strain, suitable for the expression of toxic proteins 30 , is susceptible to 184 carbapenems. We generated a derivative of C43 that allows for IPTG-dependent expression 185 a plasmid-based copy of axc (E. coli_Axc (JC107)). Susceptibility testing for imipenem and 186 meropenem showed that the MICs for these carbapenems increased 8-fold, following 187 induction of Axc expression (Table 1) . Though these levels were lower than for the positive 188 control (KPC) for our assay, they were specific for Axc as the expression of an unrelated 189 protein (PPEP-1 31 ) did not lead to an increase in MIC values (Table 1) . Thus, expression of 190 Axc is correlated to resistance towards carbapenems. 191 To directly demonstrate carbapenemase activity, hydrolysis of imipenem was 192 monitored in vitro through colorimetric assays ( Figure 3A ) and 1 H-NMR ( Figure 3B ). was observed with E. coli_Axc grown in the presence, but not in the absence, of IPTG. 208 Hydrolysis was also apparent for KPC, but not for E. coli cells expressing PPEP-1 209 (E.coli_control)), even after long incubation times (10h). Under these conditions, imipenem 210 hydrolysis was also observed for samples with E. coli cells harbouring the Axc expression 211 plasmid grown in absence of IPTG, due to leaky expression from the inducible promoter. 212 Taken together, our data establish that Axc has carbapenemase activity. highlight that mass spectrometry approaches can be used to gain insight in the mechanism 242 of action and role of specific proteins in the observed phenotypes. 243 We do not know whether the high level of Axc is the only mechanism conferring AxyX and 10 vs 2 for AxyY in the results presented in Figure 1 ). However, the difference is 279 not as pronounced as found for Axc and more accurate quantitative proteomics 280 experiments have to be performed to validate these data. 281 Mutations in TetR-like repressors have been linked to differences in carbapenem resistance For the second proteomics approach, in-solution digests were prepared as described 364 previously 23 . In short, following cell disruption proteins were solubilized in 50% 365 trifluoroethanol (TFE). Subsequent reduction with DTT and alkylation with IAA were 366 performed prior to overnight tryptic digestion. Samples were lyophilized and reconstituted 367 in 0.5% TFA for injection. The nano-LC system and solvents were the same as in the above 368 experiment, but using an Acclaim PepMap RSLC column (C18, 75 µm x 50cm with 2 µm 369 particles, Thermo Scientific) with a 2 cm Acclaim PepMap100 guard column (Thermo 370 Scientific). Peptides were eluted from the column with a multi-step gradient from 5% to 55% 371 of solvent B in 180 minutes, at a constant flow rate of 300 nl min -1 . MS analysis was carried 372 out as described above.
373
Mass spectrometry data export and spectral count analysis 375 Conversion of Bruker Impact files into mzXML format using CompassXport version 3.0.9, led 376 to an initial total of 1,207,329 MS/MS and 444,565 MS/MS spectra, for the gel and total 377 lysate based comparisons, respectively (in-solution total lysate digests were analysed twice 378 and the data were merged). These spectra were searched using a concatenated forward and were Sanger sequenced at a commercial provider (Macrogen, Amsterdam, the Netherlands). 423 PCR products (for primers see Table 3 ) were sequenced using the same primers as those 424 used for generating the product from genomic DNA isolated from the A. xylosoxidans 425 isolates. We have submitted the Axc sequence to Genbank, ID MF767301. 426 To construct an E. coli strain expressing Axc with a C-terminal 6xHis-tag from an IPTG 427 (isopropyl β-D-1-thiogalactopyranoside) inducible promoter, the axc open reading frame 428 was amplified using primers Axfor2 and Axrev3 (Table 3) 
